Who founded OS Therapies?

OS Therapies was founded by Paul Romness in 2018.

Who are OS Therapies's investors?

OS Therapies's investors include K20 Fund, Jefferies.

How much funding has OS Therapies raised?

OS Therapies has disclosed $31.3M raised across 11 of its 13 known rounds.

Where is OS Therapies headquartered?

OS Therapies is headquartered in Grasonville, US.

OS Therapies

NYSE: OSTX

Grasonville, US · Founded 2018 · Delaware corporation · 2 known investors

Find your way into OS Therapies

Paths you didn't know you had: your email and LinkedIn already hold routes to the OS Therapies team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

OS Therapies (OST) is a clinical-stage cancer immunotherapy company developing treatments that activate the immune system to target HER2-expressing cancers, initially focusing on osteosarcoma in children and adults. It plans to expand its lead candidate into breast, colorectal, esophageal, lung, ovarian, and pancreatic cancers and other solid tumors.

Biotech Healthtech

Founders & leadership

OS Therapies was founded in 2018 by Paul Romness.

Paul Romness Founder · CEOPaul Romness is founder and CEO of OS Therapies, a clinical-stage cancer immunotherapy company developing HER2-targeted treatments. He has held senior executive roles in biopharmaceutical companies focused on strategy, business development, and commercial operations.

Christopher P. Acevedo Chief Financial OfficerChristopher P. Acevedo is CFO of OS Therapies, a clinical-stage cancer immunotherapy company. He previously worked in public accounting at a major U.S. firm focusing on real estate audits, later transitioned to tax work managing portfolios and advising closely held businesses, and has experience executing acquisitions and taking companies public.

Robert G. Petit Chief Medical Officer and Chief Scientific OfficerRobert G. Petit is Chief Medical Officer and Chief Scientific Officer at OS Therapies, a clinical-stage cancer immunotherapy company. He has held executive and scientific roles in immunology and oncology drug development at both major pharmaceutical companies and biotechs, including leading the US medical team for Yervoy through regulatory approval and commercial launch, discovering the mechanism of action for Saforis and advancing it through Phase 3 clinical trials at Aesgen Inc., and contributing to the invention of multiple cancer immunotherapy candidates.

Gerald Commissiong Chief Business OfficerGerald Commissiong served as CEO of Todos Medical, an in-vitro diagnostics company developing blood tests for early cancer and neurodegenerative disease detection, and as president and executive chairman of Amarantus Bioscience Holdings, a biopharmaceutical company developing therapies and diagnostics across multiple disease areas. He is currently a managing partner at Fortitude Advisors, providing executive and financial advisory services to biotechnology companies.

Board

John CiccioBoard director

Theodore F. SearchBoard director

Olivier R. Jarry Non Executive DirectorExecutive Officer at Klothea Bio

Avril McKean DieserBoard director

Craig EagleBoard director

Investors · 2

K20 Fundlisted by K20 FundValley Stream · $100K – $2.5M

JefferiesreportedNew York

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$31.3M disclosed across 11 of 13 rounds · 1900–2026

▶$5MraisedAug 2026 · 10 investors · Biotechnology

Rule 506(b)